STOCK TITAN

Immuron Ltd - IMRN STOCK NEWS

Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.

Immuron Ltd (ASX: IMRN) provides investors and industry stakeholders with timely updates through this centralized news resource. Track the Australian biopharmaceutical innovator's progress in developing oral immunotherapies targeting gastrointestinal and immune-mediated disorders.

Access verified announcements covering clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection includes updates on Immuron's hyperimmune bovine colostrum platform, product pipeline advancements, and financial disclosures - all essential for understanding the company's position in the immunotherapy sector.

Key focus areas include Travelan® commercialization efforts, research into non-alcoholic fatty liver disease treatments, and novel applications of polyclonal antibody technology. Bookmark this page for efficient monitoring of Immuron's progress in addressing unmet needs across gastroenterology and immunology markets.

Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has appointed Steven Lydeamore as CEO, effective June 27, 2022. With 30 years of pharmaceutical experience, including roles at Apotex and Mayne Pharma, Lydeamore has a strong background in mergers, acquisitions, and product development. He aims to leverage opportunities for Immuron's products, Travelan® and Protectyn®, and enhance the company's IP portfolio. Interim CEO Dr. Jerry Kanellos will transition to COO, acknowledging the challenges faced during his tenure. The company is focused on expanding clinical trials in partnership with the U.S. Department of Defense.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
management
-
News
Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported strong sales growth for its gastrointestinal supplement Travelan® in Q3 FY22. North American sales surged 185% year-over-year, while global sales increased by 216%, totaling AU $193K compared to AU $61K in Q3 FY21. Year-to-date results show AU $392K in worldwide sales, marking a 340% increase. Sales in the US reached AU $153K for Q3 FY22, primarily driven by partnerships with Passport Health Travel Clinics and e-commerce platforms. Positive sales trends are attributed to the recovery of international travel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
none
-
Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has made significant progress in its bid for additional funding from the U.S. Department of Defense. The company is seeking AU$5.4M (US$4M) for its Travelan product, deemed eligible for award. The Investigational New Drug application is advancing, with plans for a clinical trial involving 60 healthy volunteers in the USA. This trial will focus on preventing travelers' diarrhea caused by bacterial pathogens, amidst concerns regarding antibiotic resistance and the need for effective preventive treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
none
Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has appointed Paul Brennan as an independent Non-Executive Director, effective March 16, 2022. Brennan's extensive healthcare experience includes his role as CEO of PolyNovo Limited, where he grew the company significantly. His appointment is expected to leverage Immuron's unique intellectual property in gut health and enhance its clinical research capabilities. Non-Executive Chairman Dr. Roger Aston expressed confidence in Brennan's diverse background, which includes technology commercialization and international marketing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
management
-
Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical firm, has successfully claimed a cash refund of AUD $306,154 under the Australian Government’s Research and Development Income Tax Concession program. This refund pertains to eligible research and development expenses from the 2021 Financial Year. The company is committed to developing oral immunotherapeutics for gut-mediated pathogens.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, has received a European Patent for treating travelers' diarrhea. The patent, granted on January 5, 2022, covers 'Composition and method for the treatment and prevention of enteric bacterial infections.' This extends Immuron's patent coverage across multiple regions, including Australia, India, Canada, and the US. Given the rising antibiotic resistance in enteric pathogens, this patent validates a preventative approach that addresses a critical health issue prevalent among travelers and military personnel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.09%
Tags
none
Rhea-AI Summary

Immuron Limited has secured AU $4.8 million (USD $3.43 million) from the U.S. Department of Defense for its product Travelan. Additionally, the company received AU $1.4 million (USD $1.02 million) from the U.S. Naval Medical Research Center to support Travelan's clinical development. The total funding of AU $6.2 million (USD $4.45 million) will be used to test a single larger dosing regimen for military applications. A clinical trial involving 60 volunteers will assess the efficacy of Travelan against Enterotoxigenic Escherichia coli.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.18%
Tags
none
-
Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced a clinical trial program to evaluate the efficacy of Travelan® and two non-antibiotic OTC products for Travelers' Diarrhea. The Uniformed Services University (USU) commenced manufacturing investigational products in November 2021, anticipating enrollment to start in April 2022. The trial aims to enroll 1,336 participants over 18 months, assessing three nutraceuticals against a placebo. This initiative involves collaboration with USU’s Infectious Diseases Clinical Research Program and other organizations to enhance health strategies for travel risk.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
-
Rhea-AI Summary

Immuron Limited has announced the successful completion of its investigational medical product manufacturing for the US Naval Medical Research Centre (NMRC) after a year-long hiatus due to COVID-19. The company plans to submit an IND application to the U.S. FDA in Q1 2022 to initiate two human Phase II trials. One trial aims to prevent infectious diarrhea caused by ETEC, while the second focuses on campylobacteriosis. Both trials will take place at Johns Hopkins Bloomberg School of Public Health, with the first expected to commence in H1 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
none
Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced a significant advancement in its antiviral research with the publication of findings regarding its product IMM-124E. Conducted by Hadassah Medical Center, the study, titled Augmented antiviral T cell immunity by oral administration of IMM-124E, outlines results from a preclinical mouse model and a phase I/IIa clinical trial. The research indicated that IMM-124E promotes antiviral T cell responses against various viral strains, including SARS-CoV-2 and Hepatitis B. The company has also filed an international patent application for IMM-124E.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.1%
Tags
none
Immuron Ltd

Nasdaq:IMRN

IMRN Rankings

IMRN Stock Data

10.84M
5.84M
0.1%
0.31%
Biotechnology
Healthcare
Link
Australia
Carlton